Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Devenlafaxine in perimenopausal and postmenopausal women with major depressive disorder
ChiCTR2400092914Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Shanxi Medical University
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of desvenlafaxine in major depressive disorder (MDD), sponsored by First Affiliated Hospital of Shanxi Medical University. Primary endpoint: Change in HAM-D17 score from baseline after 8 weeks of treatment. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
desvenlafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2400092914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092914.